Genetic immunization against cervical carcinoma: Induction of cytotoxic T lymphocyte activity with a recombinant alphavirus vector expressing human papillomavirus type 16 E6 and E7

Gene Therapy

Volumn 7, Issue 21, 2000, Pages 1859-1866

  Daemen, T ^a   Pries, F ^a   Bungener, L ^a   Kraak, M ^a   Regts, J ^a   Wilschut, J ^a  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

Author keywords

CTL; E6; E7; Human papilloma virus; Semliki Forest virus vector

Indexed keywords

BETA LACTAMASE; CANCER VACCINE; CD4 ANTIGEN; CD8 ANTIGEN; CHROMIUM 51; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G ANTIBODY; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; ONCOPROTEIN; PENICILLIN G; RECOMBINANT PROTEIN; REGULATOR PROTEIN; STREPTOMYCIN; VIRUS DNA; VIRUS PROTEIN; VIRUS RNA; VIRUS VACCINE; VIRUS VECTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER IMMUNOTHERAPY; CANCER PREVENTION; CANCER RISK; CONDYLOMA; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; FEMALE; GENE THERAPY; GENETIC RECOMBINATION; HIGH RISK POPULATION; IMMUNIZATION; IMMUNOFLUORESCENCE; IMMUNOSTIMULATION; MALIGNANT TRANSFORMATION; MOUSE; NONHUMAN; PRECANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; SEMLIKI FOREST ALPHAVIRUS; T LYMPHOCYTE ACTIVATION; TREATMENT OUTCOME; UTERINE CERVIX CARCINOMA; VIRUS EXPRESSION; VIRUS RECOMBINANT; VIRUS RECOMBINATION; WART VIRUS; WESTERN BLOTTING;

ALPHAVIRUS; ANIMALIA; DNA VIRUSES; HUMAN PAPILLOMA VIRUS; HUMAN PAPILLOMAVIRUS; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPES; MURINAE; RABBIT FIBROMA VIRUS; RNA VIRUSES; SEMLIKI FOREST VIRUS;

EID: 0033693269     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3301257     Document Type: Article

References (38)

1. Viruses in human cancer
2. Interactions of HPV E6 and E7 with tumor suppressor gene products
3. Association of human pap-illomavirus types 16 and 18 E6 proteins with p53
4. The human papillomavirus E6/E7 genes induce discordant changes in the expression of cell growth regulatory proteins
5. Interactions of human papillomavirus E7 protein with cell cycle regulators
6. Both conserved region 1 (CR1) and CR2 of the human papillomavirus type 16 E7 oncogene are required for induction of epidermal hyperplasia and tumor formation in transgenic mice
7. Gynecological malignancies in immunosup-pressed organ homograft recipients
8. High frequency of latent and clinical human papillomavirus cervical infections in immunocomprised human immunodeficiency virus-infected women
9. Vaccination with cytotoxic T lymphocyte epitope containing peptide protects against a tumor induced by human papillomavirus type-16-transformed cells
10. Cytotoxic T lymphocytes raised against a subdominant epitope offered as a synthetic peptide eradicate human papillomavirus type 16-induced tumors
11. Specificity of human cytotoxic T lymphocytes induced by a human papillomavirus type 16 E7-derived peptide
12. Immunization with human papillomavirus type 16 (HPV16) oncoprotein-loaded dendritic cells as well as protein in adjuvant induces MHC class I-restricted protection to HPV16-induced tumor cells
13. The alphaviruses: Gene expression, replication, and evolution
14. In vitro mutagenesis of a full-length cDNA clone of Semliki Forest virus: The small 6,000-molecular-weight membrane protein modulates virus release
15. A new generation of animal cell expression vectors based on the Semliki Forest virus replicon
16. Semliki Forest virus expression system: Production of conditionally infectious recombinant particles
17. The full-length E6 protein of human papillomavirus type 16 has transforming and trans-activating activities and cooperates with E7 to immortalize keratinocytes in culture
18. Human papillomavirus 16 E7 protein is associated with the nuclear matrix
19. The E7 protein of human papillomavirus (HPV) type 16 expressed by recombinant vaccinia virus can be used for detection of antibodies in sera from cervical cancer patients
20. A general purification protocol for E7 proteins from 'high-and low-risk' human papillomavirus types expressed in the yeast Schizosaccharomyces pombe
21. Intracellular localization and DNA-binding properties of human papillomavirus type 18 E6 protein expressed with a baculovirus vector
22. Characterization of the interactions of human papillomavirus type 16 E6 with p53 and E6-associated protein in insect and human cells
23. Peptide vaccination can lead to enhanced tumor growth through specific T-cell tolerance induction
24. Construction and characterization of a recombinant vaccinia expressing human papillomavirus proteins for immunotherapy of cervical cancer
25. Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen
26. Induction of cytotoxic T lymphocytes specific for a syngeneic tumor expressing the E6 oncoprotein of human papillomavirus type 16
27. A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer
28. Death mechanisms in cultured cells infected by Semliki Forest virus
29. Immunization with recombinant Semliki Forest virus induces protection against influenza challenge in mice
30. A new foreign policy: MHC class I molecules monitor the outside world
31. Help for cytotoxic-T-cell responses is mediated by CD40 signalling
32. Immunology. Licence to kill
33. A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell
34. T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions
35. Generation of cytotoxic and humoral immune responses by nonreplicative recombinant Semliki Forest virus
36. Outcome of immunization of Cynomolgus monkeys with recombinant Semliki Forest virus encoding human immunodeficiency virus type I envelope protein and challenge with a high dose of SHIV-4 virus
37. Two-helper RNA system for production of recombinant Semliki Forest virus particles
38. The short arm of chromosome 11 likely is involved in the regulation of the human papillomavirus type 16 early enhancer-promoter and in the suppression of the transforming activity of the viral DNA